

PharmaMar receives Medical Economics Award for the *Promotion of Health Research and Medicine*

- *Medical Economics in Spain seek to acknowledge Spanish corporations that have excelled in the areas of research, management and patient care in 2008*
- *Medical Economics Spanish Edition is a publication of Spanish Publishers Associates (SPA) in collaboration with Advanstar Medical Economics*
- *The award recognizes PharmaMar's commitment to innovative research*
- *The ceremony was chaired by Jose Martinez Olmos, Secretary of State for Health, and Jose Maria Fernández Sousa, President of Zeltia Group collected the award*
- *PharmaMar is the 7th Spanish Company and the 2nd Spanish Pharma Company in R & D spending*
- *PharmaMar demonstrated in 2007 the proof of concept of the sea as a source of drugs with the approval of Yondelis, the first Spanish anticancer drug*

Madrid, 30 January 2009: PharmaMar, the biotechnology company of Zeltia Group, leader in the development of anti-cancer drugs of marine origin, has been awarded Medical Economics Prize for the Promotion of Health Research and Medicine.

The awards seek to acknowledge outstanding achievements by businesses that have excelled in the areas of research, management and patient care in 2008. The award acknowledges PharmaMar's commitment to innovative research and development of new drugs to improve cancer treatment.

PharmaMar is the 7th Spanish company and 2nd Spanish pharmaceutical company in R&D investment. The world's oceans is PharmaMar's source of research, due to the fact that the sea contains greater biodiversity and is less explored than the earth, both qualitative advantages in the discovery of new drugs. The proof of concept of the sea as a source of drugs was confirmed in 2007 with the approval of Yondelis®, first Spanish anticancer drug.

The awards ceremony, held at the Palace Hotel in Madrid, was chaired by Jose Martinez Olmos, Secretary of State for Health, and Medical Economics management team, and Jose Maria Fernandez Sousa, President of Zeltia Group collected the award.

In his speech, José María Fernández Sousa, president of Zeltia, thanked Medical Economics for the award and stressed PharmaMar's commitment to the development of innovative drugs against cancer and to the training of highly skilled teams.

Fernandez Sousa also referred to the internationalization of biotechnology companies as a key element of Zeltia Group's business strategy.

During 2008, Zeltia Group's biotech division made significant progress in its investigations. The Group's Biotech division comprises four companies; PharmaMar, Noscira, Genomics and Sylentis with a broad portfolio of innovative compounds at various stages of development for the treatment of cancer, Alzheimer's disease, progressive supranuclear palsy, glaucoma, Chron's disease, or dry eye syndrome. They also provide DNA analysis and genetic markers services, development of diagnostic tests for early detection of cervical cancer or metabolic bone diseases and, applications for the diagnosis of viral respiratory diseases and different subtypes of herpes virus.

PharmaMar

PharmaMar is the world-leading biopharmaceutical company of the Zeltia Group, committed to advancing the treatment of cancer through the discovery and development of new marine-derived medicines. Yondelis® is the first Spanish antitumoral compound, currently marketed in the European Union for the treatment of soft tissue sarcomas in adults after failure of standard therapy. Last December 4th, 2008 PharmaMar submitted a Registration Dossier of Yondelis® in relapsed ovarian cancer (ROC) to the EMEA. A decision on the approval for this indication is expected to take place by mid-2009. PharmaMar has four novel compounds in clinical development: Yondelis® is also in Phase II studies in prostate, breast and pediatric cancers. Aplidin®, Zalypsis®, and Irvalec® are new marine-derived agents in clinical development. PharmaMar also has an extensive portfolio of products in preclinical research and a sound R&D program.

For further information:

Media Relations (Ph: +34 91 846 60 00)

Fernando Mugarza
Carlos Martínez de la Serna
Carolina Lanzas Otazu

Capital Markets (Ph: +34 91 444 45 00)

Alfonso Hurtado de Mendoza
Florencia Radizza

This press release is also available in the News Area of www.pharmamar.com